|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2004-8-12
|
|
pubmed:abstractText |
Trastuzumab is an effective treatment for patients with metastatic breast cancer (MBC) that overexpresses HER-2. A high incidence of brain metastases (BM) has been noted in patients receiving trastuzumab. A retrospective chart review was conducted of 100 patients commencing trastuzumab for metastatic breast cancer from July 1999 to December 2002, at the Christie Hospital. Seven patients were excluded; five patients developed central nervous system metastases prior to starting trastuzumab, and inadequate data were available for two. Out of the remaining 93 patients, 23 (25%) have developed BM to date. In all, 46 patients have died, and of these 18 (39%) have been diagnosed with BM prior to death. Of the 23 patients developing BM, 18 (78%) were hormone receptor negative and 18 (78%) had visceral disease. Univariate analysis showed a significant association between the development of cerebral disease and both hormone receptor status and the presence of visceral disease. In conclusion, a high proportion of patients with MBC treated with trastuzumab develop symptomatic cerebral metastases. HER-2-positive breast cancer may have a predilection for the brain, or trastuzumab therapy may change the disease pattern by prolonging survival. New strategies to address this problem require investigation in this group of patients.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/15266327-10561337,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15266327-11248153,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15266327-11332148,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15266327-11352950,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15266327-11432901,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15266327-11521729,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15266327-11576722,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15266327-11821453,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15266327-11821814,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15266327-12507088,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15266327-12784331,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15266327-12853349,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15266327-2470152,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15266327-3755076,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15266327-3798106,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15266327-3806159,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15266327-498057,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15266327-6640506,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15266327-7308254
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-2,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Estrogen,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Progesterone,
http://linkedlifedata.com/resource/pubmed/chemical/trastuzumab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0007-0920
|
|
pubmed:author |
pubmed-author:ByrdL ALA,
pubmed-author:ClaytonA JAJ,
pubmed-author:DansonSS,
pubmed-author:HowellAA,
pubmed-author:JollySS,
pubmed-author:MageeBB,
pubmed-author:RyderW D JWD,
pubmed-author:StewartA LAL,
pubmed-author:WardleyA MAM,
pubmed-author:WelchR SRS,
pubmed-author:WilkinsonP MPM,
pubmed-author:WilsonGG
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
16
|
|
pubmed:volume |
91
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
639-43
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:15266327-Adult,
pubmed-meshheading:15266327-Aged,
pubmed-meshheading:15266327-Antibodies, Monoclonal,
pubmed-meshheading:15266327-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:15266327-Antineoplastic Agents,
pubmed-meshheading:15266327-Breast Neoplasms,
pubmed-meshheading:15266327-Central Nervous System Neoplasms,
pubmed-meshheading:15266327-Female,
pubmed-meshheading:15266327-Humans,
pubmed-meshheading:15266327-Incidence,
pubmed-meshheading:15266327-Middle Aged,
pubmed-meshheading:15266327-Receptor, erbB-2,
pubmed-meshheading:15266327-Receptors, Estrogen,
pubmed-meshheading:15266327-Receptors, Progesterone,
pubmed-meshheading:15266327-Retrospective Studies,
pubmed-meshheading:15266327-Risk Factors
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer.
|
|
pubmed:affiliation |
Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Withington, Manchester M20 4BX, UK.
|
|
pubmed:publicationType |
Journal Article
|
